US-based C2N Diagnostics, LLC, a specialty diagnostics company with a vision to bring Clarity Through Innovation, has announced a $10 million investment from Korea's Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation. C2N says Samsung’s decision bolsters its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health.
Through this strategic investment, C2N aims to continue accelerating organisational capabilities with unrelenting focus to ensure patients globally have access to C2N’s best-in-class blood biomarker testing technologies for Alzheimer’s disease and related dementias. Early and accurate diagnosis is of critical importance given personal, financial, and societal impacts of Alzheimer’s disease and related dementias.
With over 50,000 Precivity analytes reported and over 150 Neuro academic, clinical, and research collaborations globally using Precivity biomarkers, C2N has significantly impacted Alzheimer’s research. C2N is now expanding the biomarker pipeline by developing advanced assays targeting tau pathology, Parkinson’s disease research, and developing technologies to decentralize mass spectrometry testing.
